418 related articles for article (PubMed ID: 29610456)
21. Discovery and validation of methylation signatures in blood-based circulating tumor cell-free DNA in early detection of colorectal carcinoma: a case-control study.
Sui J; Wu X; Wang C; Wang G; Li C; Zhao J; Zhang Y; Xiang J; Xu Y; Nian W; Cao F; Yu G; Lou Z; Hao L; Liu L; Li B; Zhang Z; Cai S; Liu H; Lan P; Zhang W
Clin Epigenetics; 2021 Feb; 13(1):26. PubMed ID: 33536049
[TBL] [Abstract][Full Text] [Related]
22. Serum methylation levels of TAC1. SEPT9 and EYA4 as diagnostic markers for early colorectal cancers: a pilot study.
Liu Y; Tham CK; Ong SY; Ho KS; Lim JF; Chew MH; Lim CK; Zhao Y; Tang CL; Eu KW
Biomarkers; 2013 Aug; 18(5):399-405. PubMed ID: 23862763
[TBL] [Abstract][Full Text] [Related]
23. Septin 9 methylated DNA is a sensitive and specific blood test for colorectal cancer.
Warren JD; Xiong W; Bunker AM; Vaughn CP; Furtado LV; Roberts WL; Fang JC; Samowitz WS; Heichman KA
BMC Med; 2011 Dec; 9():133. PubMed ID: 22168215
[TBL] [Abstract][Full Text] [Related]
24. Postoperative serum methylation levels of TAC1 and SEPT9 are independent predictors of recurrence and survival of patients with colorectal cancer.
Tham C; Chew M; Soong R; Lim J; Ang M; Tang C; Zhao Y; Ong SY; Liu Y
Cancer; 2014 Oct; 120(20):3131-41. PubMed ID: 24925595
[TBL] [Abstract][Full Text] [Related]
25. Simultaneous Analysis of SEPT9 Promoter Methylation Status, Micronuclei Frequency, and Folate-Related Gene Polymorphisms: The Potential for a Novel Blood-Based Colorectal Cancer Biomarker.
Ravegnini G; Zolezzi Moraga JM; Maffei F; Musti M; Zenesini C; Simeon V; Sammarini G; Festi D; Hrelia P; Angelini S
Int J Mol Sci; 2015 Dec; 16(12):28486-97. PubMed ID: 26633373
[TBL] [Abstract][Full Text] [Related]
26. SEPT9: A Specific Circulating Biomarker for Colorectal Cancer.
Song L; Li Y
Adv Clin Chem; 2015; 72():171-204. PubMed ID: 26471083
[TBL] [Abstract][Full Text] [Related]
27. SHOX2 DNA methylation is a biomarker for the diagnosis of lung cancer in plasma.
Kneip C; Schmidt B; Seegebarth A; Weickmann S; Fleischhacker M; Liebenberg V; Field JK; Dietrich D
J Thorac Oncol; 2011 Oct; 6(10):1632-8. PubMed ID: 21694641
[TBL] [Abstract][Full Text] [Related]
28. Colorectal cancer screening with blood-based biomarkers: cost-effectiveness of methylated septin 9 DNA versus current strategies.
Ladabaum U; Allen J; Wandell M; Ramsey S
Cancer Epidemiol Biomarkers Prev; 2013 Sep; 22(9):1567-76. PubMed ID: 23796793
[TBL] [Abstract][Full Text] [Related]
29. Performance of the colorectal cancer screening marker Sept9 is influenced by age, diabetes and arthritis: a nested case-control study.
Ørntoft MB; Nielsen HJ; Ørntoft TF; Andersen CL;
BMC Cancer; 2015 Oct; 15():819. PubMed ID: 26514170
[TBL] [Abstract][Full Text] [Related]
30. The performance of the SEPT9 gene methylation assay and a comparison with other CRC screening tests: A meta-analysis.
Song L; Jia J; Peng X; Xiao W; Li Y
Sci Rep; 2017 Jun; 7(1):3032. PubMed ID: 28596563
[TBL] [Abstract][Full Text] [Related]
31. A systematic review of the performance of the SEPT9 gene methylation assay in colorectal cancer screening, monitoring, diagnosis and prognosis.
Song L; Yu H; Jia J; Li Y
Cancer Biomark; 2017; 18(4):425-432. PubMed ID: 28128742
[TBL] [Abstract][Full Text] [Related]
32. Diagnostic and prognostic value of SHOX2 and SEPT9 DNA methylation and cytology in benign, paramalignant, and malignant ascites.
Jung M; Pützer S; Gevensleben H; Meller S; Kristiansen G; Dietrich D
Clin Epigenetics; 2016; 8():24. PubMed ID: 26937257
[TBL] [Abstract][Full Text] [Related]
33. Performance of epigenetic markers SEPT9 and ALX4 in plasma for detection of colorectal precancerous lesions.
Tänzer M; Balluff B; Distler J; Hale K; Leodolter A; Röcken C; Molnar B; Schmid R; Lofton-Day C; Schuster T; Ebert MP
PLoS One; 2010 Feb; 5(2):e9061. PubMed ID: 20140221
[TBL] [Abstract][Full Text] [Related]
34. Circadian Rhythm of Methylated Septin 9, Cell-Free DNA Amount and Tumor Markers in Colorectal Cancer Patients.
Tóth K; Patai ÁV; Kalmár A; Barták BK; Nagy ZB; Galamb O; Wichmann B; Tulassay Z; Molnár B
Pathol Oncol Res; 2017 Jul; 23(3):699-706. PubMed ID: 28035516
[TBL] [Abstract][Full Text] [Related]
35. Multiplex methylated DNA testing in plasma with high sensitivity and specificity for colorectal cancer screening.
Zhao G; Li H; Yang Z; Wang Z; Xu M; Xiong S; Li S; Wu X; Liu X; Wang Z; Zhu Y; Ma Y; Fei S; Zheng M
Cancer Med; 2019 Sep; 8(12):5619-5628. PubMed ID: 31407497
[TBL] [Abstract][Full Text] [Related]
36. The performance of the mSEPT9 assay is influenced by algorithm, cancer stage and age, but not sex and cancer location.
Song L; Jia J; Yu H; Peng X; Xiao W; Gong Y; Zhou G; Han X; Li Y
J Cancer Res Clin Oncol; 2017 Jun; 143(6):1093-1101. PubMed ID: 28224298
[TBL] [Abstract][Full Text] [Related]
37. Combined SEPT9 and BMP3 methylation in plasma for colorectal cancer early detection and screening in a Brazilian population.
Lima AB; Dos Reis MB; Matsushita M; Dos Reis MT; de Oliveira MA; Reis RM; Guimarães DP
Cancer Med; 2023 Aug; 12(15):15854-15867. PubMed ID: 37338022
[TBL] [Abstract][Full Text] [Related]
38. Application of droplet digital polymerase chain reaction of plasma methylated septin 9 on detection and early monitoring of colorectal cancer.
Ma ZY; Chan CSY; Lau KS; Ng L; Cheng YY; Leung WK
Sci Rep; 2021 Dec; 11(1):23446. PubMed ID: 34873218
[TBL] [Abstract][Full Text] [Related]
39. Diagnostic Assessment of septin9 DNA Methylation for Colorectal Cancer Using Blood Detection: A Meta-Analysis.
Sun G; Meng J; Duan H; Zhang D; Tang Y
Pathol Oncol Res; 2019 Oct; 25(4):1525-1534. PubMed ID: 30488278
[TBL] [Abstract][Full Text] [Related]
40. Association of the SHOX2 and RASSF1A methylation levels with the pathological evolution of early-stage lung adenocarcinoma.
Zhao J; Lu Y; Ren X; Bian T; Feng J; Sun H; Liu L; She B; Liu Y; Ke H
BMC Cancer; 2024 Jun; 24(1):687. PubMed ID: 38840077
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
